Neutropenia is the situation where the number of neutrophils in the blood is too low. Neutrophils play an important role in defending the body against bacterial infections and thus a patient with few neutrophils is more susceptible to bacterial infections. Neutropenia is the most serious hematologic toxicity of cancer chemotherapy and it often limits the doses of chemotherapy that can be tolerated and Neutropenia complications may also lead to treatment delays, or early treatment termination, compromising disease control and the potential for cure.
Certain chemotherapy regimens and chemotherapy doses are more likely to cause neutropenia. Although it seems counterintuitive, neutropenic fevers are more likely to occur in the first cycle of chemotherapy compared with later cycles. Furthermore, those patients who do experience chemotherapy-induced neutropenia in the first cycle are more likely to experience
Get FREE sample copy at: https://www.delveinsight.com/sample-request/chemotherapy-induced-febrile-neutropenia-market
The Chemotherapy-Induced Febrile Neutropenia Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Chemotherapy-Induced Febrile Neutropenia market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Chemotherapy-Induced Febrile Neutropenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chemotherapy-Induced Febrile Neutropenia Market Key Facts
-
According to DelveInsight estimates, the total incident population of the top ten cancer indications in the 7 major markets was the highest in the United States at 1,029,396 cases in 2017.
-
The overall number of cancer patients included in the report, which is at low risk of developing CIFN (Chemotherapy-Induced Febrile Neutropenia) was found to be 45,471 in 2017.
-
According to Cancer Research UK, Prostate cancer is the second most common cancer in the UK and accounts for 13% of all new cases in the UK. Prostate cancer is the most common cancer in males in the UK (2014), accounting for 26% of all new cases of cancer in males.
-
Among the EU5 countries, Germany had the highest number of incident cases followed by France and the UK.
Key Benefits of Chemotherapy-Induced Febrile Neutropenia Market Report
-
Chemotherapy-Induced Febrile Neutropenia market report provides an in-depth analysis of Chemotherapy-Induced Febrile Neutropenia Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Chemotherapy-Induced Febrile Neutropenia Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers the Chemotherapy-Induced Febrile Neutropenia current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Chemotherapy-Induced Febrile Neutropenia market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Chemotherapy-Induced Febrile Neutropenia Market
The Chemotherapy Induced Febrile Neutropenia market size is expected to increase during the forecast period owing to the launch of upcoming therapies and the increase in the geriatric population in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Chemotherapy-Induced Febrile Neutropenia market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Chemotherapy-Induced Febrile Neutropenia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Chemotherapy-Induced Febrile Neutropenia Epidemiology
The epidemiology section covers insights about the historical and current Chemotherapy-Induced Febrile Neutropenia patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Chemotherapy Induced Febrile Neutropenia Epidemiology Segmentation
-
Cases of Ten Major Cancer Indications
-
Ten Cancer indications with Major incidence of CIFN
-
Cancer Patients with low-risk CIFN, split by Top 10 Cancer Indications in 7 MM
-
Cancer Patients with Intermediate to High-Risk CIFN, Split By Top 10 Cancer Indications
Chemotherapy-Induced Febrile Neutropenia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy-Induced Febrile Neutropenia market or expected to get launched in the market during the study period. The analysis covers Chemotherapy-Induced Febrile Neutropenia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Chemotherapy-Induced Febrile Neutropenia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Chemotherapy-Induced Febrile Neutropenia market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Chemotherapy-Induced Febrile Neutropenia emerging therapies.
Chemotherapy Induced Febrile Neutropenia Companies:
-
Amgen
-
Apotex
-
Mylan
-
Biocon
-
Hospira
-
Pfizer
-
USV Biologics
-
Accord Healthcare
-
Coherus Biosciences
-
Enzychem Lifesciences
-
Sandoz Pharmaceuticals
-
Fuji Pharma Co., Ltd.
-
Generon (Shanghai) Corporation
-
Myelo Therapeutics
-
Teva Pharmaceuticals
-
Spectrum Pharmaceuticals
-
BeyondSpring Pharmaceuticals
And many others.
Chemotherapy Induced Febrile Neutropenia Therapies covered in the report include:
-
Plinabulin
-
Rolontis
-
Myelo001
-
F-627
-
PEG-Filgrastim
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Chemotherapy-Induced Febrile Neutropenia Competitive Intelligence Analysis
4. Chemotherapy-Induced Febrile Neutropenia Market Overview at a Glance
5. Chemotherapy-Induced Febrile Neutropenia Disease Background and Overview
6. Chemotherapy-Induced Febrile Neutropenia Patient Journey
7. Chemotherapy-Induced Febrile Neutropenia Epidemiology and Patient Population
8. Chemotherapy-Induced Febrile Neutropenia Treatment Algorithm, Current Treatment, and Medical Practices
9. Chemotherapy-Induced Febrile Neutropenia Unmet Needs
10. Key Endpoints of Chemotherapy-Induced Febrile Neutropenia Treatment
11. Chemotherapy-Induced Febrile Neutropenia Marketed Products
12. Chemotherapy-Induced Febrile Neutropenia Emerging Therapies
13. Chemotherapy-Induced Febrile Neutropenia Seven Major Market Analysis
14. Attribute Analysis
15. Chemotherapy-Induced Febrile Neutropenia Market Outlook (7 major markets)
16. Chemotherapy-Induced Febrile Neutropenia Access and Reimbursement Overview
17. KOL Views on the Chemotherapy-Induced Febrile Neutropenia Market.
18. Chemotherapy-Induced Febrile Neutropenia Market Drivers
19. Chemotherapy-Induced Febrile Neutropenia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/chemotherapy-induced-febrile-neutropenia-market
Latest Reports By DelveInsight
Chemotherapy Induced Febrile Neutropenia Pipeline Insights
Chemotherapy Induced Febrile Neutropenia Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Chemotherapy Induced Febrile Neutropenia market.
Klebsiella Pneumoniae Infections Market
DelveInsight’s “Klebsiella Pneumoniae Infections Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Klebsiella Pneumoniae Infections market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/